SUPERCOMNET TECHNOLOGIES BHD
KLSE (MYR): SCOMNET (0001)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
1.20
Today's Change
-0.02 (1.64%)
Day's Change
1.20 - 1.22
Trading Volume
685,400
Financial
Market Cap
Market Cap
1,033 Million
NOSH
861 Million
Latest Quarter
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
27-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
22-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
4.43% | 15.18%
T4Q Result
Revenue | NP to SH
141,782.000 | 31,866.000
RPS | P/RPS
16.47 Cent | 7.28
EPS | P/E | EY
3.70 Cent | 32.41 | 3.09%
DPS | DY | Payout %
1.87 Cent | 1.56% | 50.52%
NAPS | P/NAPS
0.50 | 2.42
QoQ | YoY
3.6% | 4.42%
NP Margin | ROE
22.48% | 7.48%
F.Y. | Ann. Date
30-Jun-2024 | 27-Aug-2024
Latest Audited Result
Latest Audited Result
31-Dec-2023
Announcement Date
30-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
30-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Annual (Unaudited)
Revenue | NP to SH
138,055.000 | 29,727.000
RPS | P/RPS
16.04 Cent | 7.48
EPS | P/E | EY
3.45 Cent | 34.74 | 2.88%
DPS | DY | Payout %
1.80 Cent | 1.50% | 52.22%
NAPS | P/NAPS
0.42 | 2.83
YoY
-9.93%
NP Margin | ROE
21.53% | 8.15%
F.Y. | Ann. Date
31-Dec-2023 | 28-Feb-2024
Annualized Result
Revenue | NP to SH
148,850.000 | 32,918.000
RPS | P/RPS
17.30 Cent | 6.94
EPS | P/E | EY
3.82 Cent | 31.37 | 3.19%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
2.22% | 14.94%
NP Margin | ROE
22.11% | 7.72%
F.Y. | Ann. Date
30-Jun-2024 | 27-Aug-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 3 / 4 | 75.00% | 3 / 8 | 37.50% |
| Total Positive Profit Years | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Profit Growth | 4 / 4 | 100.00% | 6 / 8 | 75.00% |
| Continuous Quarters Of Adjusted EPS Growth | 4 / 4 | 100.00% | 6 / 8 | 75.00% |
| Total Dividend Years | 2 / 4 | 50.00% | 4 / 8 | 50.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 2.07% | 2.17% | ||
| Average Net Profit Margin | 22.49% | 21.17% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Positive Profit | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Profit Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Dividend Years | 5 / 5 | 100.00% | 6 / 10 | 60.00% |
| Continuous Quarters Of Dividend | 5 / 5 | 100.00% | 5 / 10 | 50.00% |
| Continuous Quarters Of Dividend Growth | 4 / 5 | 80.00% | 4 / 10 | 40.00% |
| Continuous Quarters Of Adjusted Dps Growth | 5 / 5 | 100.00% | 5 / 10 | 50.00% |
| Average ROE | 8.98% | 7.47% | ||
| Average Net Profit Margin | 18.53% | 13.25% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 141,782 | 148,850 | 138,055 | 91,482 | 138,640 |
| NP to SH | 31,866 | 32,918 | 29,727 | 15,029 | 25,885 |
| Dividend | 16,097 | 25,075 | 15,524 | 6,292 | 12,389 |
| Adjusted EPS | 3.70 | 3.82 | 3.45 | 1.75 | 3.01 |
| Adjusted DPS | 1.87 | 2.91 | 1.80 | 0.73 | 1.44 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 5.93% | 14.85% | 5.27% | 8.01% | 3.83% |
| NP to Owner | 4.43% | 15.18% | 14.94% | 5.54% | 7.82% |
| Dividend | 0.00% | 0.00% | 7.77% | 0.00% | 0.00% |
| Adjusted EPS | 4.43% | 15.18% | 14.94% | 5.54% | 7.82% |
| Adjusted DPS | 0.00% | 0.00% | 7.77% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.70% | 2.27% | 54.98% | 7.82% | 7.36% | 62.71% | -12.80% | -0.42% | 50.91% |
| NP to Owner | 7.20% | 23.10% | 112.02% | 10.73% | 27.17% | 119.02% | -9.93% | 14.84% | 97.79% |
| Dividend | 3.69% | 29.93% | 155.84% | 61.52% | 102.39% | 298.52% | 1.91% | 25.30% | 146.73% |
| Adjusted EPS | 7.20% | 23.10% | 112.02% | 10.73% | 27.17% | 119.02% | -9.93% | 14.84% | 97.79% |
| Adjusted DPS | 3.69% | 29.93% | 155.84% | 61.52% | 102.39% | 298.52% | 1.91% | 25.30% | 146.73% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
7 people like this. Showing 50 of 4,418 comments
Investors are smart enough to know who’s the tin kosong (ie fruitcake) who just know how to make noise and post statements with NO substance…
2024-01-17 19:36
wow, wat happened? Why the directors disposed the shares continuously?
2024-02-08 10:00
Buy call scomnet 1.30
Tp 1.80 range.
Is it real.will say yes.ini kali lah.
15/2/24 3.55pm
2024-02-15 15:55
Probably as Ambu's order has been recovering since the third quarter of last year
2024-02-26 15:51
Price is rather high (PE 34x) while future upside is not that great..
Mermaid orders would be halted in April this year. Though it’s mentioned to be resumed by Sept when internal dispute is settled, there is uncertainty whether the dispute can be settled by then..
better wait for it the price to be cheaper first then only enter..
2024-03-06 10:07
Be cautious of this company.
Between August 2020 and March 2024,
they have continually added 170,117,400 shares through additional listings, which dilutes shareholder benefits. This trend of adding approximately 3,956,218 shares per month continues.
The management of this listed company is not sincere in fostering business growth;
instead, they manipulate share units for their own benefit.
2024-03-07 19:35
c328 ,
the Company issued FREE warrant of 1:3 to all existing shareholders on 2019, then they are eligible to convert warrant at RM0.65 per share (which the price are similar at the mother share price at 2019). So the convertion is a REWARD to shareholders who hold long term.
2024-03-08 08:14
ha.. lets the market take time to digest all the dilution impact and production line impact first.
2024-03-08 23:36
Analysis of Scomnet from TA research. Quite good
https://www.thestar.com.my/business/business-news/2024/03/06/medical-segment-to-drive-supercomnet-earnings
2024-03-12 09:44
Management sold too fast 😆
https://klse.i3investor.com/web/insider/detail/D_178307_150721058
2024-04-29 14:56
omg today volume huge.
now only two distinct directions :-
1) Fly uppp and away
2) Crash and hard landing
You have to bet which direction it goes..
2024-04-29 16:04
Nice, epf started tapping in 🤗
https://klse.i3investor.com/web/insider/detail/SBSH_584740_174085760
2024-05-06 10:17
nope. it's normal, when have Exercise of Warrants - 2,224,166 shares at 0.650. Just wait.
2024-05-08 10:58
Watch out for results announcement today or tomorrow. More excitment ahead
2024-05-20 15:57
Q1 result was out. Net profit improved QoQ and YoY due to increased in sales of medical products with better profit margin
2024-05-21 10:10
nice, EPF chipped in again
https://klse.i3investor.com/web/insider/detail/SBSH_586680_3225427302
2024-05-29 11:00
Europe stocks extend losses after worst session for a month; Royal Mail owner IDS up 4% on sale agreement
Jenni Reid
2024-05-29 23:01
Scomnet is expected to rake in net profit of RM39.15 million this year, according to Bloomberg, compared to RM29.73 million in the previous year.
2024-06-04 17:26
Supercomnet looks for another shot in the arm in medical segment
https://theedgemalaysia.com/node/719123
2024-07-23 20:20
Commendable Q2 results but share price doesn't react ...
https://www.dagangnews.com/article/jualan-segmen-perubatan-supercomnet-pada-separuh-kedua-2024-diunjur-meningkat-kata-ta-securities-40338
2 months ago
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-21 16:50:00
EMA 5
5 Mins
SELL
2024-11-21 16:50:00
MACD/RSI
5 Mins
SELL
2024-11-21 16:40:00
EMA 5
10 Mins
BUY
2024-11-21 16:40:00
EMA 5
5 Mins
BUY
2024-11-21 15:40:00
EMA 5
10 Mins
SELL
Apps
Top Articles
1
2
Good Articles to Share
3
4
Koon Yew Yin's Blog
Why all plantation companies will continue to report more profit - Koon Yew Yin
5
AmInvest Research Reports
6
7
save malaysia!
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Xcalibre
Medical Segment Sets to Grow Further
Moving into 4Q23, the group is confident that the medical segment contribution will increase by 15-20% QoQ driven by higher sales to Edward (40% of 3Q23 revenue) and recovery in orders from Ambu (29% of 3Q23 revenue). We note that Supercomnet has been chosen by Edwards Lifesciences (market cap of above USD50bn) as the best quality supplier (more than 700 suppliers) and achieved gold status in 2023. Edward will be using more digital smart cable (from analog cable) for its products such as its inbuilt PCB Board somewhere in the middle of 2024. For Ambu, the growth will come from endoscopes, gastroscopes and colonoscope (US FDA approved in Sep-23).
2024-01-17 14:40